Fig. 1: The Serum Epitope Repertoire Analysis (SERA) platform enables high-resolution mapping of SARS-CoV-2 antibody repertoires. | Communications Biology

Fig. 1: The Serum Epitope Repertoire Analysis (SERA) platform enables high-resolution mapping of SARS-CoV-2 antibody repertoires.

From: High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19

Fig. 1

The SERA assay results in a set of ~1 million unique peptides, the “epitope repertoire”, for each individual. Repertoires were deposited in a database and compared with pre-pandemic controls to identify conserved epitopes in SARS-CoV-2 using proteome-dependent and -independent bioinformatic methods. SERA enables analysis of COVID-19 repertoires against any proteome including mutant SARS-CoV-2 strains, human common coronaviruses and the human proteome for discovery of potential autoantigens. The identified epitope signatures can be used to build diagnostic classifiers, to identify correlates of disease severity, and to develop hypotheses based on cases with specific symptoms and/or disease course (neurological, GI, cardio e.g.).

Back to article page